Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Causal inference from longitudinal studies with baseline randomization.

Toh S, Hernán MA.

Int J Biostat. 2008 Oct 19;4(1):Article 22. doi: 10.2202/1557-4679.1117.

2.

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause.

Prentice RL, Manson JE, Langer RD, Anderson GL, Pettinger M, Jackson RD, Johnson KC, Kuller LH, Lane DS, Wactawski-Wende J, Brzyski R, Allison M, Ockene J, Sarto G, Rossouw JE.

Am J Epidemiol. 2009 Jul 1;170(1):12-23. doi: 10.1093/aje/kwp115. Epub 2009 May 25.

3.

Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.

Hernán MA, Alonso A, Logan R, Grodstein F, Michels KB, Willett WC, Manson JE, Robins JM.

Epidemiology. 2008 Nov;19(6):766-79. doi: 10.1097/EDE.0b013e3181875e61.

4.

HRT in the early menopause: scientific evidence and common perceptions.

Pines A, Sturdee DW, Birkhauser MH, de Villiers T, Naftolin F, Gompel A, Farmer R, Barlow D, Tan D, Maki P, Lobo R, Hodis H; International Menopause Society..

Climacteric. 2008 Aug;11(4):267-72. doi: 10.1080/13697130802226866. No abstract available.

PMID:
18645691
5.

The effect of epoetin dose on hematocrit.

Cotter D, Zhang Y, Thamer M, Kaufman J, Hernán MA.

Kidney Int. 2008 Feb;73(3):347-53. Epub 2007 Nov 14.

6.

Hormones and heart disease in women: the timing hypothesis.

Barrett-Connor E.

Am J Epidemiol. 2007 Sep 1;166(5):506-10.

PMID:
17849510
7.

Invited commentary: hormone therapy and risk of coronary heart disease why renew the focus on the early years of menopause?

Manson JE, Bassuk SS.

Am J Epidemiol. 2007 Sep 1;166(5):511-7. Epub 2007 Jul 23.

PMID:
17646204
8.

HRT and the young at heart.

Mendelsohn ME, Karas RH.

N Engl J Med. 2007 Jun 21;356(25):2639-41. No abstract available.

PMID:
17582075
9.

Estrogen therapy and coronary-artery calcification.

Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Cochrane BB, Hunt JR, Ludlam SE, Pettinger MB, Gass M, Margolis KL, Nathan L, Ockene JK, Prentice RL, Robbins J, Stefanick ML; WHI and WHI-CACS Investigators..

N Engl J Med. 2007 Jun 21;356(25):2591-602.

10.

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, Ko M, LaCroix AZ, Margolis KL, Stefanick ML.

JAMA. 2007 Apr 4;297(13):1465-77. Erratum in: JAMA. 2008 Mar 26;299(12):1426.

PMID:
17405972
11.
12.

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial.

Prentice RL, Langer R, Stefanick ML, Howard BV, Pettinger M, Anderson G, Barad D, Curb JD, Kotchen J, Kuller L, Limacher M, Wactawski-Wende J; Women's Health Initiative Investigators..

Am J Epidemiol. 2005 Sep 1;162(5):404-14. Epub 2005 Jul 20.

PMID:
16033876
13.
14.

Menopausal symptoms and treatment-related effects of estrogen and progestin in the Women's Health Initiative.

Barnabei VM, Cochrane BB, Aragaki AK, Nygaard I, Williams RS, McGovern PG, Young RL, Wells EC, O'Sullivan MJ, Chen B, Schenken R, Johnson SR; Women's Health Initiative Investigators..

Obstet Gynecol. 2005 May;105(5 Pt 1):1063-73.

PMID:
15863546
15.

Executive summary. Hormone therapy.

American College of Obstetricians and Gynecologists Women's Health Care Physicians..

Obstet Gynecol. 2004 Oct;104(4 Suppl):1S-4S. No abstract available.

PMID:
15458927
16.
17.

Estrogen plus progestin and the risk of coronary heart disease.

Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators..

N Engl J Med. 2003 Aug 7;349(6):523-34.

18.

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators..

JAMA. 2002 Jul 17;288(3):321-33.

PMID:
12117397
19.

Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.

Hernán MA, Brumback B, Robins JM.

Epidemiology. 2000 Sep;11(5):561-70.

PMID:
10955409
20.

Marginal structural models and causal inference in epidemiology.

Robins JM, Hernán MA, Brumback B.

Epidemiology. 2000 Sep;11(5):550-60.

PMID:
10955408

Supplemental Content

Support Center